Episode Details

Back to Episodes
Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Season 7 Episode 391 Published 1 month, 2 weeks ago
Description

Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington.
The analysts also discuss the complexities of Beam's trade secret suit against YolTech, why the GLOBE Medicare pricing model matters more for the precedent it sets than for its savings, and the Nobel Prize for optogenetics as the first therapy based on the technology nears an FDA decision.

View full story: https://www.biocentury.com/article/661028

#ChinaBiotech #DrugPricing #IntellectualProperty #DrugDevelopment #NobelPrize

0:00 Introduction
1:30 China Pharma Deal Trends
11:29 Beam vs. YolTech Lawsuit
20:01 Small GLOBE, Big Precedent
24:05 Nobel Prize & Optogenetics

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us